Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Obinutuzumab in Richter's Transformation
NCT03145480Phase 2Terminated
- Sponsor
- Northwell Health
- Start
- Jun 2017
- Primary completion
- Sep 2018
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibrutinib and obinutuzumab in Richter's syndrome (RS) (2 arms), sponsored by Northwell Health. Primary endpoint: Overall Response Rate at 6 months. Started Jun 2017; status: terminated.
02
Drugs
ibrutinibobinutuzumab
03
Conditions
Richter's syndrome (RS)
Beyond the preview
Go deeper on NCT03145480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145480.